Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887373 | 0.85 | ALDH1A1 (0.35) | ALDH1A1FDPS | |
| SCHEMBL24396 | 0.79 | ALDH1A1 (0.32) | ALDH1A1CYP2D6 | |
| SCHEMBL10060803 | 0.78 | — | — | |
| SCHEMBL14577005 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CYP2D6 | |
| SCHEMBL14024194 | 0.75 | GABRR1 (0.30) | — | |
| SCHEMBL14450798 | 0.75 | — | — | |
| SCHEMBL22060031 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL23228848 | 0.74 | CYP2D6 (0.45) | ALDH1A1FDPSCYP2D6 | |
| SCHEMBL11337447 | 0.74 | ALDH1A1 (0.45) | ALDH1A1FDPSCYP2D6 | |
| SCHEMBL16335742 | 0.74 | ALDH1A1 (0.38) | ALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940814-B2 | Dispersions comprising functionalized oxidic nanoparticles | BASF SE (DE) | 2015-01-27 | — | — | US | disclosed |
| EP-2738198-A1 | Enzymatic synthesis of polyamide in aqueous mini-emulsion | Henkel AG & Co. KGaA (DE) | 2014-06-04 | — | — | EP | disclosed |
| EP-2376564-A2 | DISPERSIONS COMPRISING FUNCTIONALIZED OXIDIC NANOPARTICLES | BASF SE (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245391-A1 | DISPERSIONS COMPRISING FUNCTIONALIZED OXIDIC NANOPARTICLES | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066768-A2 | DISPERSIONS COMPRISING FUNCTIONALIZED OXIDIC NANOPARTICLES | BASF SE (DE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100036052-A1 | PROCESS FOR PREPARING POLYMERS FILLED WITH NANOSCALE METAL OXIDES | BASF SE (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-2089467-A2 | METHOD FOR PRODUCING NANOSCALE METAL OXIDE-FILLED POLYMERS | BASF SE (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080275182-A1 | Method For Producing An Aqueous Polyamide Dispersion | BASFAKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080199925-A1 | Method For Producing an Aqueous Polymer Dispersion | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080194771-A1 | Method for the Production of an Aqueous Polymer Dispersion | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1819754-A2 | METHOD FOR PRODUCING AN AQUEOUS POLYAMIDE DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1819826-A1 | METHOD FOR PRODUCING AN AQUEOUS POLYAMIDE DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| WO-2006131479-A1 | METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006122922-A1 | METHOD FOR THE PRODUCTION OF AN AQUEOUS POLYMER DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006106138-A1 | METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006082234-A1 | METHOD FOR THE PRODUCTION OF AN AQUEOUS POLYMER DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006058697-A1 | METHOD FOR PRODUCING AN AQUEOUS POLYAMIDE DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006058696-A2 | METHOD FOR PRODUCING AN AQUEOUS POLYAMIDE DISPERSION | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885FDPS 250/4885CYP2D6 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.